Valneva IPO Presentation Deck

Valneva Has a Specialist Travel Vaccine Business and is a Contractor to the US Military Prior to the pandemic, Valneva demonstrated a strong track record of sales growth built upon the solid foundation of its business relationship with the US DOD €129.5m of product sales in 2019 (+25% AER, +22% CER) ¹ Direct sales channels in the US, Canada, UK, France, Nordics, and Austria ■ Distributors in Germany, Australia/NZ and smaller markets Marketing & Distribution of 3rd party specialty vaccines² Three year supply deal with US Military/Dept of Defense representing a base value of $135m if options are exercised Valneva believes that the commercial business is a key asset for the future, e.g. chikungunya route to market, once the travel industry recovers Valneva reports record product sales and major pipeline progress in 2019. Valneva and Bavarian Nordic Announce Marketing and Distribution Partnership Valneva - Roadshow Presentation April 2021 35

View entire presentation